Comparison of the diagnostic accuracy of ca27.29 and Ca I 5.3 in Primary breast cancer

Clinical Chemistry

Volumn 45, Issue 5, 1999, Pages 630-637

  Gion, Massimo ^a   Mione, Riccardo ^a   Leon, Antonette E ^a   Dittadi, Ruggero ^a  

^a Campo SS Giovanni e Paolo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; AUTOANALYSIS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CHEMILUMINESCENT MEASUREMENTS; FEMALE; HUMANS; REAGENT KITS, DIAGNOSTIC; REFERENCE VALUES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0032896605     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. 1. Gum JR. Mucin genes and the proteins they encode: structure, diversity and regulation. Am J Respir Cell Mol Biol 1992;7:557-64.
2. 2. Gender S, Spicer AP, Lalani E-N, Duhig T, Peat N, Burchell J, et al. Structure and biology of a carcinoma associated mucin, MUC-1. Am Rev Respir Dis 1991;S42-7.
3. 3. Graves R, Hilgers J, Fritsche H, Hayes D, Robertson JFR. MUC-1 mucin assays for monitoring therapy in metastatic breast cancer. Breast 1998;7:181-6.
4. 4. Taylor-Papadimitriou J. Report on the First International Workshop on carcinoma-associated mucins. Int J Cancer 1991;49:1-5.
5. 5. Tobias R, Rothwell C, Wagner J, Green A, Liu YSW. Development and evaluation of radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D8/DF3 [Abstract]. Clin Chem 1985;31:986.
6. 6. Hilkens J, Buij F, Hilgers J, Hageman P, Calafat J, Sonnenberg A, van der Valk MA. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 1984;34:197-206.
7. 7. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3:223-31.
8. 8. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, et al. Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996 [Review]. Tumor Biol 1998;19(Suppl 1):1-20.
9. 9. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
10. 10. American Society of Clinical Oncology. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1998;16:793-5.
11. 11. Chan DW, Beveridge RA, Muss H, Fritsche HA, Hortobagyi G, Theriault R, et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 1997;15:2322-8.
12. 12. Reddish MA, Helbrecht N, Almeida AF, Madiyalakan R, Suresh MR, Longenecker BM. Epitope mapping of Mab 827.29 within the peptide core of the malignant breast carcinoma-associated mucin antigen coded for by the human MUC1 gene. J Tumor Marker Oncol 1992;7:19-27.
13. 13. Correale M, Abbate I, Gargano G, Catino A, Dragone CD, Musci MD, et al. Analytical and clinical evaluation of a new tumor marker in breast cancer: CA27.29. Int J Biol Markers 1992;7:43-6.
14. 14. Rodriguez de Patema L, Arnaiz J, Estenoz J, Ortuno B, Lanzos E. Study of serum tumor markers CEA, CA15.3 and CA27.29 as diagnostic parameters in patients with breast carcinoma. Int J Biol Markers 1995;10:24-9.
15. 15. Jensen JL, MacLean GD, Suresh MR, Almeida A, Jette D, Lloyd S, et al. Possible utility of serum determinations of CA125 and CA27.29 in breast cancer management. Int J Biol Markers 1991;6:1-6.
16. 16. Hayes DF, Zurawski VR, Kufe D. Comparison of circulating CA15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986;4:1542-50.
17. 17. Devine PL, Duroux MA, Quin RJ, McGuickin MA, Joy GJ, Ward BG, Pollard CW. CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer. Breast Cancer Res Treat 1995;34:245-51.
18. 18. Eastbrook A, Chen J, Oster M, Salinen R, Yemul S, Leon J. Clinical value of BCA 225: a new breast cancer serum marker. J Tumor Marker Oncol 1994;9:111-8.
19. 19. Gion M, Mione R, Nascimben O, Valsecchi M, Gatti C, Leon A, Bruscagnin G. The tumor associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. Br J Cancer 1991;63:809-13.
20. 20. O'Hanlon DM, Kerin MJ, Kent P, Maher D, Grimes H, Given HF, et al. An evaluation of preoperative CA15.3 measurement in primary breast carcinoma. Br J Cancer 1995;71:1288-91.
21. 21. Peterson JA, Ceriani RL. Breast mucin and associated antigens in diagnosis and therapy. In: Ceriani RL, ed. Antigen and antibody molecular engineering in breast cancer diagnosis. New York: Plenum, 1994:2-3.
22. 22. Roth HJ, Zahn I, Maimonis P. Performance characteristics of the ACS-BR: a comparison with three other assays that also measure CA15.3. Clin Lab 1995;41:1031-5.
23. 23. Bon GG, von Mensdorff-Pouilly S, Kenemans P, van Kamp GJ, Verstraeten RA, Hilgers J, et al. Clinical and technical evaluation of ACS-BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA15.3 assays. Clin Chem 1997;43:585-93.
24. 24. European Organization for Research and Treatment of Cancer. Revision of the standards for the assessment of hormone receptors in human breast cancer. Report of the Second E.O.R.T.C. Workshop held on 16-17 March 1979, in the Netherlands Cancer Institute. Eur J Cancer 1980;16:1513-20.
25. 25. Dixon AR, Price MR, Hand CV, Sibley PE, Selby C, Blamey RW. Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer. A comparison with CA15.3. Br J Cancer 1993;68:947-9.
26. 26. Safi F, Kohler I, Rottinger E, Suhr P, Beger HG. Comparison of CA15.3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989;4:207-14.
27. 27. Kallioneimi OP, Oksa H, Aaran RK, Hietanen T, Lehtinen M, Koivula T, et al. Serum CA15.3 assay in the diagnosis and follow-up of breast cancer. Br J Cancer 1988;58:213-5.
28. 28. Miserez AR, Günes I, Müller-Brand J, Walther E, Fridrich R, Macke H, et al. Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA15.3. Eur J Cancer 1991;27:126-31.
29. 29. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC. Evaluation of CA M26, CA M29, CA15.3 and CEA as circulating tumor markers in breast cancer patients. Tumor Biol 1991;12:82-90.
30. 30. Schol DJ, Meulenbroek MFA, Snijdewint FGM, von Mensdorff-Pouilly S, Verstraeten RA, Murakami F, et al. 'Epitope fingerprinting' using overlapping 20-mer peptides of the MUC-1 tandem repeat sequence. Tumor Biol 1998;19:35-45.
31. 31. Spencer DIR, Price MR, Tendler SJB, De Matteis CI, Stadie T, Hanisch FG. Effect of glycosylation of a synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies. Cancer Lett 1996;100:11-5.
32. 32. Gourevitch MM, Mensdorff-Pouilly S, Litvinov SV, Kenemans P, van Kamp GJ, Verstraeten RA, Hilgers J. Polymorphic epithelial mucin (MUC-1) containing circulating immune complexes in carcinoma patients. Br J Cancer 1995;72:934-8.
33. 33. Molina R, Filella X, Mengual P, Prats M, Zanon G, Daniels M, Ballesta AM. MCA in patients with breast cancer: correlation with CEA and CA15.3. Int J Biol Markers 1990;5:14-21.
34. 34. Crippa F, Bembardieri E, Seregni E, Castellani MR, Gasparini M, Maffioli L, et al. Single determination of CA15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer. J Nucl Biol Med 1992;36:52-5.
35. 35. Colomer R, Ruibal A, Genolla J, Rubio D, Del Campo JM, Bodi R, Salvador L. Circulating CA15-3 levels in the postsurgical follow-up of breast cancer patients in non-malignant diseases. Breast Cancer Res Treat 1989;13:123-33.
36. 36. Soletormos G, Nielsen D, Schioler V, Skovsgaard T, Winkel P, Mouridsen HT, Dombernowsky P. A novel method for monitoring high-risk breast cancer with tumor markers: CA15.3 compared to CEA and TPA. Ann Oncol 1993;4:861-9.
37. 37. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995;36:41-8.
38. 38. Bombardieri E, Gion M, Mione R, Dittadi R, Bruscagnin G, Buraggi G. A mucinous-like carcinoma-associated antigen (MCA) in the tissue and blood of patients with primary breast cancer. Cancer 1989;63:490-5.
39. 39. Gion M, Plebani M, Mione R, Penzo C, Meo S, Burlina A. Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA. Br J Cancer 1994;69:721-5.
40. 40. Aspeslet L, Ballok J, Mansbach L, Maimonis PJ. A technical and clinical evaluation of 3 commercial MUC-1 breast cancer marker assays [Abstract]. Tumor Biol 1998;19(Suppl 2):13.
41. 41. Laine RA. A calculation of all possible oligosaccharide isomers, both branched and linear yields 1.05 x 10(12) structures for a reducing hexasaccharide: the Isomer Barrier to development of single-method saccharide sequencing or synthesis systems. Glycobiology 1994;4:759-67.